Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
about
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
description
2018 nî lūn-bûn
@nan
2018年の論文
@ja
2018年学术文章
@wuu
2018年学术文章
@zh-cn
2018年学术文章
@zh-hans
2018年学术文章
@zh-my
2018年学术文章
@zh-sg
2018年學術文章
@yue
2018年學術文章
@zh
2018年學術文章
@zh-hant
name
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@en
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@nl
type
label
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@en
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@nl
prefLabel
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@en
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@nl
P2093
P2860
P50
P356
P1476
Pharmacokinetics, safety, and ...... imeprevir in healthy subjects.
@en
P2093
Alain Patat
Caroline Denot
Christopher Westland
David Apelian
David B Smith
Gwendoline Poizat
Jennifer Vuong
Laure Viguerie
Marie-Claude Homery
P2860
P304
P356
10.1002/PRP2.395
P577
2018-04-30T00:00:00Z